Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026
Basics
Sector
Healthcare
Industry
Health Information Services
Country
United States
Market cap
1.6B USD
Enterprise value
1.9B USD
Full-time employees
4,648
Overall health
Drawback:less profitable than most peersless profitable than peers
Drawback:growing more slowly than most peersgrowing more slowly than peers
Drawback:higher risk than most peers: its share price swings more than most peers’ (beta 2.13 vs a peer median of 0.63), less short-term liquidity (current ratio 0.83 vs a peer median of 2.59) and more debt relative to equity (0.79× vs a peer median of 0.22×)higher risk: bigger price swings (beta 2.13 vs peers 0.63), less liquidity (current ratio 0.83 vs peers 2.59) and more debt vs equity (0.79× vs peers 0.22×)
About average: valuation
Ranks #995 of 1,157 healthcare companies (bottom 15%)
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Teladoc Health looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Teladoc Health reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
More volatile share price. Beta 2.13: tends to move more than the market.
Teladoc Health's shares have swung more with the market than most peers' (beta 2.13, above the market's 1.0).
StockQuotient Score
29/ 100Oct 5 30 → Nov 4 29 (-1)Fundamentals: Yahoo Finance, not primary filings
Why it changed since the Oct 27, 2026 close: Score 43 → 41
Share price +37.8%-4
Peer companies moved+2
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Sector-normalized EBITDA, earnings, and free cash flow yields.
Earnings yield-11.1%
Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Teladoc Health
Is Teladoc Health getting weaker?
Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is unchanged at 29/100 since Oct 28, 2026.
How is Teladoc Health valued vs its peers?
Priced about in line with its peers. Valuation scores 41/100 against 1,393 healthcare peers.Earnings yield -11.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.1% vs peers 1.5% (weaker than 100% of peers).
Is Teladoc Health growing?
More slowly than most of its peers. Growth scores 30/100 against 1,393 healthcare peers.Revenue growth -1.5% vs a peer median of 6.1% (weaker than 73% of peers).Revenue growth -1.5% vs peers 6.1% (weaker than 73% of peers).
How profitable is Teladoc Health?
Less profitable than most of its peers. Profitability scores 32/100 against 1,393 healthcare peers.Return on invested capital -7.1% vs a peer median of 4.7% (weaker than 73% of peers).Return on invested capital -7.1% vs peers 4.7% (weaker than 73% of peers).
How risky is Teladoc Health?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Beta 2.13 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.13 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Detailed annual statements come from structured SEC filing data, which most US companies and some foreign filers provide. They aren’t available for this company yet.
TDOC price history
Price history is added with the daily price update and will appear after the next one.